Biochemical aspects of dementias.

The ubiquitin system. Annu Rev Biochem (1998) 43.36

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (1997) 28.30

Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology (1998) 26.77

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature (2002) 19.36

Alzheimer's disease: genes, proteins, and therapy. Physiol Rev (2001) 19.19

Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet (1998) 12.92

Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature (2002) 10.81

Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med (1996) 10.44

Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell (1993) 10.15

Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A (1986) 10.13

Neurodegenerative tauopathies. Annu Rev Neurosci (2001) 9.53

Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science (2001) 6.17

Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science (2001) 6.00

Toxic proteins in neurodegenerative disease. Science (2002) 5.82

Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J Neurol Neurosurg Psychiatry (1994) 5.40

Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature (2002) 5.32

Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci (2001) 5.32

The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci (2001) 5.29

Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science (1992) 5.22

Shattuck lecture--neurodegenerative diseases and prions. N Engl J Med (2001) 4.75

Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc Natl Acad Sci U S A (1999) 4.71

Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci U S A (1994) 4.33

Amyloid fibrils from muscle myoglobin. Nature (2001) 3.93

Review: history of the amyloid fibril. J Struct Biol (2000) 3.49

Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study. BMJ (1995) 3.42

A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature (2001) 3.28

Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. Proc Natl Acad Sci U S A (1999) 2.51

Frontotemporal dementia. Br J Psychiatry (2002) 1.95

Familial multiple system tauopathy with presenile dementia: a disease with abundant neuronal and glial tau filaments. Proc Natl Acad Sci U S A (1997) 1.89

Patterns of risk in first-degree relatives of patients with Alzheimer's disease. Arch Gen Psychiatry (1994) 1.84

Neuropathology of synuclein aggregates. J Neurosci Res (2000) 1.40

Alpha synuclein in neurodegenerative disorders: murderer or accomplice? Nat Med (1998) 1.21

Incidence of Creutzfeldt-Jakob disease in Switzerland. Lancet (2002) 1.20

Dementia with Lewy bodies. Br J Psychiatry (2002) 1.18

Assessment of genetic risk for Alzheimer's disease among first-degree relatives. Ann Neurol (1989) 1.17

Prions: health scare and biological challenge. Nat Rev Mol Cell Biol (2001) 1.10

Clinical aspects of human spongiform encephalopathies, with the exception of iatrogenic forms. Biomed Pharmacother (1999) 1.08

The significance of tau and alpha-synuclein inclusions in neurodegenerative diseases. Curr Opin Genet Dev (2001) 1.04

Interventional strategies against prion diseases. Nat Rev Neurosci (2001) 0.99

Bovine spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease. Curr Opin Neurobiol (1997) 0.93

Structure/function of alpha-synuclein in health and disease: rational development of animal models for Parkinson's and related diseases. J Neurochem (2002) 0.90

Diagnostic challenges in dementia. Neurology (1998) 0.88

Dementia associated with Lewy bodies: dilemmas and directions. Arch Neurol (1999) 0.83

Genomic organization and expression of the human beta-synuclein gene (SNCB). Genomics (1998) 0.82

Pathogenesis of prion diseases: a progress report. Cell Death Differ (2000) 0.81

Dementia and neuropathology in Lewy body disease. Adv Neurol (1993) 0.81

Neuropathology of human prion diseases (spongiform encephalopathies). Dev Biol Stand (1993) 0.79

Picking away at frontotemporal dementia. Neurology (2002) 0.79

Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat Med (2002) 2.12